Biosynth Showcasing at CPHI North America in Philadelphia

news-releasesBiosynth

April 16th 2024

Staad, Switzerland: – Biosynth is a supplier of critical raw materials, and services for diagnostics, vaccines and pharmaceuticals with global research, manufacturing, and distribution facilities. Biosynth AG will be prominent presence as an exhibitor in the API Zone of the North American edition of the pharma industry’s leading event series, CPHI.

Extensive range

The Biosynth stand at Booth 1202 at the North America Pennsylvania Convention Center in Philadelphia, PA, will showcase its very extensive range of chemical, pharmaceutical and biotech products, including therapeutic peptides and complex fine chemicals.

Biosynth’s presence in Philadelphia will be led by its Business Development Manager, Dr. Gerard Palau, and San Diego-based Account Manager Andrew Foote.

End-to-end capabilities

“We are very pleased to be returning to CPHI North America,” commented Dr. Palau.

“This is one of our most important markets and we will take advantage of the event’s high profile and superb networking opportunities to highlight our now very extensive group capabilities to handle all aspects of a complex project from first idea to finished product, as well as the scale and scope we can bring to our mission to streamline life sciences industry supply chains across Complex Chemicals, Peptides and Key Biologics.”

Biosynth provides a full range of products and services to support life science research and development, with more than half a million products in its research catalog and hundreds of complex manufacturing service projects. It has become a trusted supplier, manufacturer and partner for the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics. The group has facilities across three continents and a rapid global distribution network for chemicals produced from milligram to ton scale and up to multikilogram scale, all to ISO 9001 and cGMP quality standards.

About Biosynth

Biosynth is a supplier of critical raw materials, and services for diagnostics, vaccines and pharmaceuticals with global research, manufacturing, and distribution facilities. Supplying the pharmaceutical and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation.

With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability spans Complex Chemicals, Peptides, and Key Biologics, all from one trusted partner.  Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners, and management.

Find out more about Biosynth at www.Biosynth.com

About CPHI North America 2024

CPhI North America made its debut in 2017 as a new development of the highly successful CPhI worldwide franchise first established in 1989. Originally conceived as chemical and pharmaceutical ingredients show, CPhI is now a global series of events for the whole pharmaceutical value chain, taking in events all over the world attracting more than 100,000 attendees annually.

The seventh CPhI North America Expo is a three-day event opening May 7, 2024, at the North America Pennsylvania Convention Center in Philadelphia, PA. It brings together seven shows in one, co-locating CPhI Connect for pharmaceutical ingredients with six other zones, including Informex (fine and specialty chemicals), iCSE (drugs development) FDF (finished drug products), P-Mec (Machinery), and InnoPack for packaging.

The conference is powered by three tracks of programming covering Drug Development, Drug Manufacturing and Bioprocessing.

CPhI North America is staged by leading Global B2B events organizer and publisher UBM Live, with more information at: https://cphinorthamerica.com/